Actively Recruiting
Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-16
100
Participants Needed
1
Research Sites
213 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for: * predicting response to immune-therapeutic regimens in HCC in the early phase of treatment, * to rule out pseudo-progression, * to early predict the escape from effectiveness of treatment.
CONDITIONS
Official Title
Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of hepatocellular carcinoma (HCC)
- Ability to have laboratory tests, treatments, and follow-up at the study center
- Provided written informed consent to participate in the study
You will not qualify if you...
- Presence of immune-related concomitant diseases
- HIV infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS-Azienda Ospedaliero-Universitaria di Bologna
Bologna, Laura Gramantieri, Italy, 40138
Actively Recruiting
Research Team
L
Laura Gramantieri, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here